Blueprint Medicines (BPMC) USPTO patentsUtility grant

Utility

Compositions useful for treating disorders related to KIT

28 Nov 23

Compounds and compositions useful for treating disorders related to mutant KIT are described herein.

Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang

Filed: 9 Nov 22

Utility

EGFR inhibitors

8 Aug 23

Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson

Filed: 8 Aug 22

Utility

Inhibitors of activin receptor-like kinase

25 Apr 23

Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian Lewis Hodous, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin

Filed: 29 May 20

Utility

MAP4K1 inhibitors

27 Dec 22

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof.

Jason D. Brubaker, Chandrasekhar V. Miduturu, Michael J. Burke, Thomas A. Dineen, Joseph L. Kim, Joshua T. Close, Emanuele Perola

Filed: 14 Jan 21

Utility

Inhibitors of RET

22 Mar 22

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro

Filed: 29 Jan 20

Utility

RET inhibitor for use in treating cancer having a RET alteration

15 Mar 22

Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.

Erica Evans Raab, Beni B. Wolf

Filed: 18 Dec 20

Utility

PRKC fusions

1 Mar 22

The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides.

Nicolas Stransky, Joseph L. Kim

Filed: 16 Jul 19

Utility

Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase

1 Feb 22

Jason D. Brubaker, Paul E. Fleming, Joseph L. Kim, Brett Williams, Brian L. Hodous

Filed: 18 Oct 18

Utility

Compounds and compositions useful for treating disorders related to NTRK

13 Jul 21

This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.

Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim

Filed: 31 Jul 19

Utility

Compounds and compositions useful for treating disorders related to NTRK

29 Jun 21

Steven Mark Wenglowsky, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, Jr.

Filed: 3 Jul 18

Utility

Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR

22 Jun 21

Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.

Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson

Filed: 29 Mar 18

Utility

Inhibitors of the fibroblast growth factor receptor

28 Dec 20

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu

Filed: 18 Feb 19

Utility

PIK3C2G fusions

28 Dec 20

The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins.

Nicolas Stransky, Ethan G. Cerami, Joseph L. Kim, Christoph Lengauer

Filed: 29 Jul 14

Utility

Compositions and methods for treating KIT- and PDGFRA-mediated diseases

9 Nov 20

Thomas A. Dineen

Filed: 7 Apr 20

Utility

Compositions useful for treating disorders related to kit

19 Oct 20

Compounds and compositions useful for treating disorders related to mutant KIT are described herein.

Kevin J. Wilson

Filed: 6 May 18

Utility

2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

14 Sep 20

Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang

Filed: 19 Dec 18

Utility

Inhibitors of activin receptor-like kinase

1 Jun 20

Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Kevin J. Wilson, Josh Waetzig

Filed: 4 Mar 19

Utility

PIK3CA fusions

1 Jun 20

The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions.

Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky

Filed: 26 Feb 19

Utility

Inhibitors of RET

9 Mar 20

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro

Filed: 19 Jul 18